4843-98-5

Basic information

• Product Name: 4-hydroxypyrazole
• Synonyms: 4-hydroxypyrazole;1H-Pyrazol-4-ol;4-Hydroxypyrazol;4-HP;InChI=1/C3H4N2O/c6-3-1-4-5-2-3/h1-2,6H,(H,4,5;Pyrazol-4-ol;4-Hydroxy-1H-pyrazole
• CAS NO: 4843-98-5
• Molecular Formula: C₃H₄N₂O
• Molecular Weight: 84.08
• EINECS: 1592732-453-0
• Mol File: 4843-98-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 326.1 °C at 760 mmHg
• Flash Point: 151 °C
• Appearance: /
• Density: 1.415 g/cm³
• Vapor Pressure: 0.000116mmHg at 25°C
• Refractive Index: 1.612
• Storage Temp.: 2-8°C
• PKA: 9.08±0.10(Predicted)
• CAS DataBase Reference: 4-hydroxypyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxypyrazole(4843-98-5)
• EPA Substance Registry System: 4-hydroxypyrazole(4843-98-5)

Safety Data

• Hazardous Substances Data: 4843-98-5(Hazardous Substances Data)

Usage

General Description

4-Hydroxypyrazole is a chemical compound with the molecular formula C3H4N2O. It is a heterocyclic organic compound and belongs to the pyrazole family. 4-Hydroxypyrazole is a pale yellow solid at room temperature and is soluble in water. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. The presence of the hydroxyl group in the molecule makes it a useful intermediate in the preparation of a variety of derivatives. Its versatile reactivity and stability make it a valuable tool for the creation of bioactive compounds with potential applications in medicine and agriculture. Furthermore, 4-hydroxypyrazole is also used as a reagent in the synthesis of organic compounds and as a ligand in coordination chemistry.

InChI:InChI=1/C3H4N2O/c6-3-1-4-5-2-3/h1-2,6H,(H,4,5)

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 23705-85-3 dimethyl 4-hydroxy-1H-pyrazole-3,5-dicarboxylate 
• 763120-58-7 1H-pyrazole-4-boronic acid 

Relevant articles and documents

Coordination Polymers as a Functional Material for the Selective Molecular Recognition of Nitroaromatics and ipso-Hydroxylation of Arylboronic Acids

We report the synthesis and structural characterization of two coordination polymers (CPs), namely; [{Zn(L)(DMF)4} ? 2BF4]α (1) and [{Cd(L)2(Cl)2} ? 2H2O]α (2) (where L=N2,N6-di(pyridin-4-yl)naphthalene-2,6-dicarboxamide). Crystal packing of 1 reveals the existence of channels running along the b- and c-axis filled by the ligated DMF and lattice anions, respectively. Whereas, crystal packing of 2 reveals that the metallacycles of each 1D chain are intercalating into the groove of adjacent metallacycles resulting in the stacking of 1D loop-chains to form a sheet-like architecture. In addition, both 1 and 2 were exploited as multifunctional materials for the detection of nitroaromatic compounds (NACs) as well as a catalyst in the ipso-hydroxylation of aryl/heteroarylboronic acids. Remarkably, 1 and 2 showed high fluorescence stability in an aqueous medium and displayed a maximum 88% and 97% quenching efficiency for 4-NPH, respectively among all the investigated NACs. The mechanistic investigation of NACs recognition suggested that the fluorescence quenching occurred via electron as well as energy transfer process. Furthermore, the ipso-hydroxylation of aryl/heteroarylboronic acids in presence of 1 and 2 gave up to 99% desired product yield within 15 min in our established protocol. In both cases, 1 and 2 are recyclable upto five cycles without any significant loss in their efficiency.

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity

A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in

SELECTIVE BETA3 ADRENERGIC AGONISTS

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β 3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I) or a pharmaceutically acceptable salt thereof. The variables of formula (I) have the meanings defined herein.